IGF-1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2026-01-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Clinical development of AOD-9604 included trials in people with obesity. Reports from early-phase and mid-phase studies described modest or inconsistent changes in body weight. A phase IIb program did not meet its primary endpoint, and the compound was not approved for medical use. Differences in formulation, delivery route, and participant characteristics may explain some of the variation. Later investigations explored whether the peptide might have effects in other tissues, including cartilage.
Regulatory treatment of AOD-9604 is shaped by its classification as a peptide hormone. The World Anti-Doping Agency lists it as a prohibited substance, and many national anti-doping organizations adopt that list. It does not hold approval as a prescription medicine in the United States, the European Union, or other major markets. Products sold online are frequently labeled for research use only and may not undergo independent quality testing. Import and possession rules differ by country, so legal status depends on local law.
| Property | Value | Notes |
|---|---|---|
| Primary research area | Obesity and metabolic regulation | Studied in cell, animal, and human models |
| Highest reported trial phase | Phase II | Public summaries describe mixed results |
| Common route in trials | Subcutaneous injection | Typical for peptide therapeutics |
| Regulatory example | 2013 Australian anti-doping review | Classification was debated at the time |
| Approval status | Not approved as a human medicine | Status can change by jurisdiction |
Interest in AOD-9604 arose from attempts to separate metabolic effects from growth effects attributed to hGH. Early work explored whether the fragment could influence lipolysis or fat oxidation without promoting growth. Those questions remain partly unresolved because human data are limited and results have varied across studies. The peptide is not a hormone replacement for hGH and is not equivalent to hGH in clinical use. Its research history includes both laboratory studies and commercial marketing claims that are not the same as regulatory approval.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
=== Score of the BLOSUM matrices === A scoring matrix or a table of values is required for evaluating the significance of a sequence alignment, such as describing the probability of a biologically meaningful amino-acid or nucleotide residue-pair occurring in an alignment. Typically, when two nucleotide sequences are being compared, all that is being scored is whether or not two bases are the same at one position. All matches and mismatches are respectively given the same score (typically +1 or +5 for matches, and -1 or -4 for mismatches). But it is different for proteins. Substitution matrices for amino acids are more complicated and implicitly take into account everything that might affect the frequency with which any amino acid is substituted for another. The objective is to provide a relatively heavy penalty for aligning two residues together if they have a low probability of being homologous (correctly aligned by evolutionary descent). Two major forces drive the amino-acid substitution rates away from uniformity: substitutions occur with the different frequencies, and lessen functionally tolerated than others. Thus, substitutions are selected against. Commonly used substitution matrices include the blocks substitution (BLOSUM) and point accepted mutation (PAM) matrices. Both are based on taking sets of high-confidence alignments of many homologous proteins and assessing the frequencies of all substitutions, but they are computed using different methods.
== History == Erythritol was discovered in 1848 by the Scottish chemist John Stenhouse and first isolated in 1852. Starting from 1945, American chemists applied newly-developed techniques of chromatography to sugarcane juice and blackstrap molasses, finding in 1950 that erythritol was present in molasses fermented by yeast. It was first approved and marketed as a sweetener in Japan in 1990, and in the US in 1997. In February 1997, Cerestar Holding Co., Mitsubishi Chemical Co., and Nikken Chemicals Co. submitted a formal generally recognized as safe (GRAS) affirmation petition with the US FDA. However, in April 1997 the FDA replaced the GRAS affirmation petition process with the current GRAS notification process, a notice was first filed by Cerestar in April 2001, and the FDA responded with "no questions" in September 2001.
where the denominator includes only covalently bound H2CO3 and does not include hydrated CO2(aq). The much smaller and often-quoted value near 4.16 × 10−7 (or pKa1 = 6.38) is an apparent value calculated on the (incorrect) assumption that all dissolved CO2 is present as carbonic acid, so that
=== InPen === The InPen is a reusable, bluetooth-enabled insulin pen, manufactured by Medtronic, that can connect to Dexcom CGM systems. The InPen can connect to the G6 and G7 through the InPen app, the Apple iPhone's Heath app, and on the Apple Watch.
Sources: en.wikipedia.org
The Yemeni crisis began with the 2011–2012 revolution against President Abdullah Saleh, who had led Yemen for 33 years. After Saleh left office in early 2012 as part of a mediated agreement between the Yemeni government and opposition groups, the government led by Saleh's former vice president, Abdrabbuh Mansur Hadi, faced challenges in governing Yemen’s divided political landscape and addressing armed opposition from Al-Qaeda in the Arabian Peninsula and the Houthi militant movement that had been waging a protracted insurgency in the north for years. In September 2014, the conflict escalated into a civil war when Houthi forces entered the capital of Sanaa and forced Hadi to negotiate a "unity government" with other political factions. The Houthis continued their advance and influence over government operations until, after forces aligned with the Houthis reportedly attacked his presidential palace and private residence, Hadi resigned along with his ministers in January 2015. The following month, the Houthis declared themselves in control of the Yemeni government, dissolving the Parliament, and installing an interim Revolutionary Committee led by Mohammed al-Houthi, a cousin of Houthi leader Abdul-Malik al-Houthi. Hadi escaped to Aden, where he declared that he remained Yemen's legitimate president, proclaimed the country's temporary capital, and called on loyal government officials and members of the military to rally to him. Beginning in 2017 the separatist Southern Transitional Council (STC) began fighting against the government.
=== Toxicity === Although zinc is an essential requirement for good health, excess zinc can be harmful. Excessive absorption of zinc suppresses copper and iron absorption. The free zinc ion in solution is highly toxic to plants, invertebrates, and even vertebrate fish. The Free Ion Activity Model is well-established in the literature, and shows that just micromolar amounts of the free ion kills some organisms. A recent example showed 6 micromolar killing 93% of all Daphnia in water. The free zinc ion is a powerful Lewis acid up to the point of being corrosive. Stomach acid contains hydrochloric acid, in which metallic zinc dissolves readily to give corrosive zinc chloride. Swallowing a post-1982 American one cent piece (97.5% zinc) can cause damage to the stomach lining through the high solubility of the zinc ion in the acidic stomach. Evidence shows that people taking 100–300 mg of zinc daily may suffer induced copper deficiency. A 2007 trial observed that elderly men taking 80 mg daily were hospitalized for urinary complications more often than those taking a placebo. Levels of 100–300 mg may interfere with the use of copper and iron or adversely affect cholesterol. Zinc in excess of 500 ppm in soil interferes with the plant absorption of other essential metals, such as iron and manganese. A condition called the zinc shakes or "zinc chills" can be induced by inhalation of zinc fumes while brazing or welding galvanized materials. Zinc is a common ingredient of denture cream which may contain between 17 and 38 mg of zinc per gram.
Colonial imperialism is the inevitable consequence in the course of economic relations among countries when the domestic price-fixing of monopoly capitalism has voided profitable competition in the capitalist homeland. The ideology of New Imperialism, rationalised as a civilising mission, allowed the exportation of high-profit investment capital to undeveloped countries with uneducated, native populations (sources of cheap labour), plentiful raw materials for exploitation (factors for manufacture) and a colonial market to consume the surplus production which the capitalist homeland cannot consume. The example is the European Scramble for Africa (1881–1914) in which imperialism was safeguarded by the national military. To secure the economic and settler colonies, foreign sources of new capital-investment-profit, the imperialist state seeks either political or military control of the limited resources (natural and human). The First World War (1914–1918) resulted from such geopolitical conflicts among the empires of Europe over colonial spheres of influence. For the colonised working classes who create the wealth (goods and services), the elimination of war for natural resources (access, control, and exploitation) is resolved by overthrowing the militaristic capitalist state and establishing a socialist state because a peaceful world economy is feasible only by proletarian revolutions that overthrow systems of political economy based upon the exploitation of labour.
== History of ITC == The history of ITC can be traced back to the 1930s when isothermal calorimetry was used to study chemical reactions. In 1965 Christensen and Izatt introduced titration calorimetry as a method for simultaneously determining the equilibrium constant and enthalpy. The ITC technique was then developed by H. D. Johnston in 1968 as a part of his Ph.D. dissertation at Brigham Young University, and was considered niche until introduced commercially by MicroCal Inc. in 1988. In 1978, Beaudette and Langerman conducted one of the earliest calorimetric binding studies using a small volume isoperibol titration calorimeter and a decade later, in 1989, Wiseman, Williston, Brandts, and Lin demonstrated its application in biological systems, marking the beginning of titration calorimetry as a valuable tool for studying biological equilibria. Originally, ITC was most often used to study the binding of small molecules (such as medicinal compounds) to larger macromolecules (proteins, DNA etc.) in a label-free environment. Its application has now broadened, aided by modern improvements, making it possible to measure the heat effects as small as 0.1 μcal (0.4 μJ) and determine the binding constants (K) as high as 108–109 M−1.
=== Natural occurrence === Nanoparticles are naturally produced by many cosmological, geological, meteorological, and biological processes. A significant fraction (by number, if not by mass) of interplanetary dust, that is still falling on the Earth at the rate of thousands of tons per year, is in the nanoparticle range; and the same is true of atmospheric dust particles. Many viruses have diameters in the nanoparticle range.
Sources: en.wikipedia.org
Most awards exclude managerial staff, and must exclude people based on the "seniority of their role" who were traditionally not covered, while "high income earners", paid over $167,500 in 2023, can agree to be exempt from an award if they have a guarantee of annual earnings. This means that, unless enterprise bargaining covers them, fair pay scales do not constrain rip-off executive pay that diminishes the pay of everyone else. Third, there are enterprise agreements, which are bargained between unions and employers to be higher, and under section 57 will displace any sector-wide award. However, in 2012, enterprise agreement coverage reached a peak of merely 27%, and by 2021 coverage fell to 15%, compared to coverages typically over 80% in European Union member states that promote sectoral collective bargaining.
== Structure and contrast with other lipids == The 2,3-sn-glycerol structure and ether bond linkage are two key differences between lipids found in archaea vs those of bacteria and eukarya. The latter use 1,2-sn-glycerol, and mostly, ester bonds. Natural archaeol has 3R, 7R, 11R configurations for the three chiral centers in the isoprenoid chains. There are four structural variations, contributing to the complexity of the membrane lipids in function and properties. The two phytanyl chains can form a 36-member ring to yield macrocyclic archaeol. Hydroxylated archaeol has phytanyl chains hydroxylated at the first tertiary carbon atom, while sesterterpanyl archaeol have the phytanyl side chains with C25 sesterterpanyl chains, substituting at C2 of glycerol or at both carbons. Unsaturated archaeol, with the same carbon skeleton as standard archaeol but one or multiple double bonds in the phytanyl side chains is also discovered.
contact inhibition Also contact inhibition of growth or density-dependent inhibition. In cell culture, the phenomenon by which most normal eukaryotic cells adhering to a planar substratum cease to grow and divide upon reaching a critical cell density, usually as they approach full confluence or come into physical contact with other cells. As a result, many types of cells cultured on plates or in Petri dishes will continue to proliferate until they cover the whole surface of the culture vessel, at which point the rate of cell division abruptly decreases or is arrested entirely, thus forming a confluent monolayer with minimal overlap between neighboring cells, even if the nutrient medium remains plentiful, rather than stacking themselves on top of each other. Transformed or neoplastic cells tend not to respond to cell density in the same way and may continue to proliferate at high densities. This type of density-dependent inhibition of growth is similar to and may occur simultaneously with, but is nonetheless distinct from, the related phenomenon of contact inhibition of movement, whereby moving cells respond to physical contact by temporarily stopping and then reversing their direction of locomotion away from the point of contact.
"H" stands for "high metal" because CH chondrites may contain up to as much as 40% of metal. That makes them one of the most metal-rich of any of the chondrite groups, second only to the CB chondrites and some ungrouped chondrites such as NWA 12273. The first meteorite discovered was ALH 85085. Chemically, these chondrites are closely related to CR and CB groups. All specimens of this group belong only to petrologic types 2 or 3.
Sources: en.wikipedia.org
No major medicines regulator appears to have approved AOD-9604 for human therapeutic use. It has been studied in clinical trials, but those programs did not result in a marketed drug.
It became prominent during a 2013 Australian sports investigation that examined whether it was a prohibited growth-hormone-related substance. Subsequent interpretations and list updates have varied, so current rules should be checked directly.
Published summaries generally report limited or inconsistent weight-loss effects, and complete trial data are not widely available. The studies were not sufficient to establish it as an effective obesity treatment.
No. Major drug regulators have not approved AOD-9604 for weight loss or any other therapeutic indication. It remains an investigational compound studied in research settings.